AMBBY:OTC-Ambu A/S (USD)

COMMON STOCK | Medical Instruments & Supplies | OTC

Last Closing Price

USD 32.26

Change

0.00 (0.00)%

Market Cap

USD 8.12B

Volume

20.00

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Ambu A/S develops, manufactures, and sells medical devices to hospitals, clinics, and rescue services worldwide. It provides healthcare solutions in the fields of visualization, anesthesia, and patient monitoring and diagnostics. The company offers endoscopy products, such as bronchoscopes and monitors, as well as related airway management products comprising video laryngoscopes, double and single lumen tubes, and endobronchial blockers; and neurology products, including EEG and EMG electrodes, EMG guided injections, and intraoperative monitoring products. It also provides cardiology products consisting of ECG electrodes; and airway management and anaesthesia products, such as bronchoscopes, video laryngoscopes, double and single lumen tubes, endobronchial blockers, laryngeal and face masks, breathing bags, and resuscitators. In addition, the company offers resuscitators, extrication collars, head immobilizers, CPR breathing barriers, suction pumps, video laryngoscopes, and training manikins. It serves hospitals, rescue services, clinics, etc. Ambu A/S was founded in 1937 and is headquartered in Ballerup, Denmark.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-12-04 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
ESLOF EssilorLuxottica Société ano..

-0.04 (-0.03%)

USD66.66B 39.62 26.76
ESLOY EssilorLuxottica Société ano..

+0.70 (+0.92%)

USD66.39B 38.78 26.76
HOCPY HOYA Corporation

-0.24 (-0.19%)

USD47.14B 49.27 0.27
HOCPF HOYA Corporation

N/A

USD46.99B 44.45 0.27
SDMHF Sartorius Stedim Biotech S.A

N/A

USD32.71B 144.46 59.34
RSMDF ResMed Inc

-2.87 (-13.24%)

USD30.32B 46.53 30.67
TRUMY Terumo Corporation

+1.22 (+3.10%)

USD29.65B 17.66 0.33
TRUMF Terumo Corporation

+0.63 (+1.57%)

USD29.62B 18.00 0.33
OCPNY Olympus Corporation

+1.15 (+5.27%)

USD27.67B 37.75 0.24
SAUHY Straumann Holding AG

+0.43 (+0.73%)

USD18.33B 69.15 81.70

ETFs Containing AMBBY

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 93.20% 74% C 81% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 93.20% 73% C 81% B-
Trailing 12 Months  
Capital Gain 87.75% 72% C- 80% B-
Dividend Return 0.33% 13% F 3% F
Total Return 88.07% 72% C- 80% B-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 10.65% N/A N/A 62% D-
Dividend Return 0.12% N/A N/A 9% F
Total Return 10.77% N/A N/A 59% F
Risk Return Profile  
Volatility (Standard Deviation) 48.45% N/A N/A 40% F
Risk Adjusted Return 22.23% N/A N/A 56% F
Market Capitalization 8.12B 72% C- 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 151.43 16% F 5% F
Price/Book Ratio 21.06 6% F 8% F
Price / Cash Flow Ratio 27.52 17% F 7% F
EV/EBITDA 15.46 41% F 22% F
Management Effectiveness  
Return on Equity 10.58% 57% F 76% C
Return on Invested Capital 10.11% 54% F 71% C-
Return on Assets 5.64% 68% D+ 87% B+
Debt to Equity Ratio 52.66% 23% F 36% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.18 72% C- 79% C+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector